Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned?
1
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
2
Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
3
Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA
Photonics 2019, 6(3), 77; https://doi.org/10.3390/photonics6030077
Received: 24 May 2019
/
Revised: 30 June 2019
/
Accepted: 1 July 2019
/
Published: 4 July 2019
(This article belongs to the Special Issue Neurophotonics – Optics for the Brain)
Next to cancer, Alzheimer’s disease (AD) and dementia is probably the most worrying health problem facing the Western world today. A large number of clinical trials have failed to show any benefit of the tested drugs in stabilizing or reversing the steady decline in cognitive function that is suffered by dementia patients. Although the pathological features of AD consisting of beta-amyloid plaques and tau tangles are well established, considerable debate exists concerning the genetic or lifestyle factors that predispose individuals to developing dementia. Photobiomodulation (PBM) describes the therapeutic use of red or near-infrared light to stimulate healing, relieve pain and inflammation, and prevent tissue from dying. In recent years PBM has been applied for a diverse range of brain disorders, frequently applied in a non-invasive manner by shining light on the head (transcranial PBM). The present review discusses the mechanisms of action of tPBM in the brain, and summarizes studies that have used tPBM to treat animal models of AD. The results of a limited number of clinical trials that have used tPBM to treat patients with AD and dementia are discussed.
View Full-Text
Keywords:
photobiomodulation; Alzheimer’s disease; dementia; mechanisms of action; animal models; clinical trials
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Hamblin, M.R. Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned? Photonics 2019, 6, 77. https://doi.org/10.3390/photonics6030077
AMA Style
Hamblin MR. Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned? Photonics. 2019; 6(3):77. https://doi.org/10.3390/photonics6030077
Chicago/Turabian StyleHamblin, Michael R. 2019. "Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned?" Photonics 6, no. 3: 77. https://doi.org/10.3390/photonics6030077
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
